FIG. 1



Part A
Dose escalation
Part B
Randomized RP2D : Placebo evaluation
Cohort 1: 2mg/kg Q2W n=6
Cohort 2: 3mg/kg Q2W n=6
Dose escalation following SRC review
Selected RP2D to be determined by SRC
Randomization
COMPOUND A at RP2D n=45
Matching placebo n=45
Follow-up
EOS
Day-2
Study treatment 12 weeks
Wk 12
Follow-up 12 weeks
Wk 24
Primary endpoint at Week 14
SRC#1 - LPI + Week 2 Cohort 1
SRC#2 - LPI + Week 6 Cohort 1
SRC#3 - LPI + Week 6 Cohort 2

FIG. 2A




FIG. 2C




FIG. 2B





FIG. 3A


Whole blood
CD4+ CD45RA+
MFI (pSTAT5)
5000
4000
3000
2000
1000
0
Comp. A
A3312F
CTL Unstim
CTL Stim 10 ng/ml
PBS
0.2 mpk
1 mpk
5 mpk
0.2 mpk
1 mpk
5 mpk
Whole blood human
CD4+ CD45RA-
8000
6000
4000
2000
2000
1500
1000
500
0
Comp. A
A3312F
CTL Unstim
CTL Stim 10 ng/ml
PBS
0.2 mpk
1 mpk
5 mpk
0.2 mpk
1 mpk
5 mpk
Whole blood human
CD8+ CD45RA+
MFI (pSTAT5)
5000
4000
3000
2000
1000
0
Comp. A
A3312F
CTL Unstim
CTL Stim 10 ng/ml
PBS
0.2 mpk
1 mpk
5 mpk
0.2 mpk
1 mpk
5 mpk
Whole blood human
CD8+ CD45RA-
MFI (pSTAT5)
5000
4000
3000
2000
1000
0
Comp. A
A3312F
CTL Unstim
CTL Stim 10 ng/ml
PBS
0.2 mpk
1 mpk
5 mpk
0.2 mpk
1 mpk
5 mpk



Splenic human CD4+ CD45RA-
Comp. A
A3312F
MFI (pSTAT)
1500
1000
500
0
CTL Unstim
PBS
0.2 mpk
1 mpk
5 mpk
0.2 mpk
1 mpk
5 mpk
Splenic human CD8+ CD45RA-
Comp. A
A3312F
MFI (pSTAT)
1400
1200
1000
800
600
CTL Unstim
PBS
0.2 mpk
1 mpk
5 mpk
0.2 mpk
1 mpk
5 mpk

FIG. 3B

FIG. 4A



IL-7 Receptor Occupancy Observed on T cells
Pooled Placebo
SAD1: .1 mg/kg
SAD2: .3 mg/kg
SAD3: 1 mg/kg
SAD4: 2 mg/kg
SAD5: 4 mg/kg
MAD1: 1 mg/kg
(Last Dose Day 43)
%RO (CD3+ T cells)
100
50
0
2
8
15
22
29
36
43
50
57
64
71
85
91
Days

FIG. 4B



Inhibition of pSTAT5 Observed in T cells
% pSTAT5+ (CD3+ T cells)
100
50
0
Pre-dose
2
8
15
22
29
36
43
50
57
64
71
85
91
Days
Pooled Placebo
SAD1: .1 mg/kg
SAD2: .3 mg/kg
SAD3: 1 mg/kg
SAD4: 2 mg/kg
SAD5: 4 mg/kg
MAD1: 1 mg/kg
(Last Dose Day 43)

FIG. 5A




Concentration (µg/mL)
10
1
0.1
5 µg/mL
Last dose
0
14
28
42
56
70
84
98
112
126
Nominal Time After Dose (Days)
2 mg/kg
3 mg/kg

FIG. 5B


Mean ± SD Receptor Occupancy (%)
100
75
50
25
0
90% RO
Last dose
0
14
28
42
56
70
84
98
112
126
140
154
168
Nominal Time After Dose (Days)
2 mg/kg
3 mg/kg
Mean ± SD RO % versus Time